Johnson & Johnson (JNJ) remains an interesting business, given the future of this diversified pharmaceutical powerhouse, as my last update on the investment case dates back January 2019 when I concluded that investors should say goodbye to growth, at least for the moment.

At this point in time Johnson & Johnson has regained operational momentum and is actually continuing bolt-on deal making. Shares continue to trade at a modest multiple given the track record and diversified operations, even with the talc litigation overhang. Right here and now, I am looking to initiate again on dips.

READ FULL ARTICLE HERE